CN1878538A - 用于治疗肥胖的mtp抑制剂的固体无定形分散体 - Google Patents

用于治疗肥胖的mtp抑制剂的固体无定形分散体 Download PDF

Info

Publication number
CN1878538A
CN1878538A CNA2004800334168A CN200480033416A CN1878538A CN 1878538 A CN1878538 A CN 1878538A CN A2004800334168 A CNA2004800334168 A CN A2004800334168A CN 200480033416 A CN200480033416 A CN 200480033416A CN 1878538 A CN1878538 A CN 1878538A
Authority
CN
China
Prior art keywords
solid amorphous
drug
amorphous dispersions
weight
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800334168A
Other languages
English (en)
Chinese (zh)
Inventor
D·T·弗里森
R·M·尚卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1878538A publication Critical patent/CN1878538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CNA2004800334168A 2003-11-14 2004-11-01 用于治疗肥胖的mtp抑制剂的固体无定形分散体 Pending CN1878538A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14
US60/519,931 2003-11-14

Publications (1)

Publication Number Publication Date
CN1878538A true CN1878538A (zh) 2006-12-13

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800334168A Pending CN1878538A (zh) 2003-11-14 2004-11-01 用于治疗肥胖的mtp抑制剂的固体无定形分散体

Country Status (16)

Country Link
US (1) US20080293801A1 (enExample)
EP (1) EP1696887A1 (enExample)
JP (1) JP2007511500A (enExample)
KR (1) KR20060096076A (enExample)
CN (1) CN1878538A (enExample)
AR (1) AR048206A1 (enExample)
AU (1) AU2004289110A1 (enExample)
BR (1) BRPI0416596A (enExample)
CA (1) CA2545443A1 (enExample)
CO (1) CO5690536A2 (enExample)
IL (1) IL175372A0 (enExample)
MX (1) MXPA06005489A (enExample)
NO (1) NO20062778L (enExample)
NZ (1) NZ546677A (enExample)
TW (1) TW200515909A (enExample)
WO (1) WO2005046644A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115052586A (zh) * 2020-02-07 2022-09-13 拜耳公司 包含瑞戈非尼和稳定剂的药物组合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619989A2 (pt) * 2005-12-15 2011-10-25 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, métodos para o tratamento e/ou prevenção de enfermidades que estão associados com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
JP5711151B2 (ja) * 2010-01-06 2015-04-30 武田薬品工業株式会社 インドール誘導体
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
RS50712B (sr) * 2001-06-28 2010-06-30 Pfizer Products Inc. Triamid-supstituisani indoli, benzofurani i benzotiofeni kao inhibitori mikrozomalnog triglicerid transfer proteina (mtp) i/ili sekrecije apolipoproteina b (apo b)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115052586A (zh) * 2020-02-07 2022-09-13 拜耳公司 包含瑞戈非尼和稳定剂的药物组合物

Also Published As

Publication number Publication date
NZ546677A (en) 2008-11-28
BRPI0416596A (pt) 2007-01-30
US20080293801A1 (en) 2008-11-27
MXPA06005489A (es) 2006-08-11
EP1696887A1 (en) 2006-09-06
CA2545443A1 (en) 2005-05-26
AR048206A1 (es) 2006-04-12
NO20062778L (no) 2006-08-14
KR20060096076A (ko) 2006-09-05
CO5690536A2 (es) 2006-10-31
JP2007511500A (ja) 2007-05-10
IL175372A0 (en) 2006-09-05
AU2004289110A1 (en) 2005-05-26
WO2005046644A1 (en) 2005-05-26
TW200515909A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
CN1207896A (zh) 提高生物利用度的固体药物分散体
TW201414469A (zh) 對包括ｖｘ-９５０之藥物實施噴霧乾燥之方法及由此方法製備之產物
CN107666914A (zh) 帕博西尼的固体剂型
JP2009149683A (ja) 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
KR20040098023A (ko) 약물 미세입자
JP2013510813A (ja) プロパン−１−スルホン酸｛３−［５−（４−クロロ−フェニル）−１Ｈ−ピロロ［２，３−ｂ］ピリジン−３−カルボニル］−２，４−ジフルオロ−フェニル｝−アミド組成物とその用途
US20100204292A1 (en) Pharmaceutical compositions comprising intra-and extra-granular fractions
CN108159019A (zh) 非索非那定微胶囊及含有非索非那定微胶囊的组合物
EP1741424B1 (en) Solid pharmaceutical dispersions with enhanced bioavailabilty
TWI729476B (zh) 纖維素粉末、其用途及錠劑
CN1509185A (zh) 医药用组合物
US9040091B2 (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
CN1878538A (zh) 用于治疗肥胖的mtp抑制剂的固体无定形分散体
JP2020189885A (ja) 顆粒の静電量を低減させる方法
CN1883456A (zh) 掩味药物颗粒及其制备方法和用途
WO2007141806A1 (en) Pharmaceutical formulations comprising oxcarbazepine and methods thereof
CN1359303A (zh) 药用复合物
HK1094533A (en) Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
CN100341495C (zh) 格列本脲固体分散体、口服组合物及其制备方法
US20090264476A1 (en) CB-1 receptor modulator formulations
US20240216347A1 (en) Bezuclastinib formulations
CN1526383A (zh) 一种甲福明和格列本脲的固体口服剂型及其制备方法
CN120617184A (zh) 一种高口服生物利用度氟苯尼考制剂制备方法
CN106177969A (zh) 增强丹参素肠道吸收的药物组合物及其制剂和制备方法
Lakshmi et al. Formulation and evaluation of aceclofenac floating microspheres

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1094533

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1094533

Country of ref document: HK